Use of indigestible oligosaccharides to prevent gastrointestinal infections and reduce duration of diarrhea in humans

• US 5,827,526 A
• Filed: 06/12/1996
• Issued: 10/27/1998
• Est. Priority Date: 07/11/1995
• Status: Expired due to Term

• Current Assignee: Abbott Laboratories Incorporated
• Original Assignee: Abbott Laboratories Incorporated
• Inventors: Ostrom, Karin Margaret, Dohnalek, Margaret Ione Halpin, Hilty, Milo Duane
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): Faulkner, D.
• Application Number:
  US08/653,084
• Time in Patent Office: 867 Days
• Field of Search: 424/197.11, 424/195.1, 424/73, 424/440, 424/439, 514/867, 514/54
• US Class Current: 424/440
• CPC Class Codes: A23C 9/1307 Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
• CPC Class Codes: A23G 2200/06 containing beet sugar or cane sugar if specifically mentioned or containing other carbohydrates, e.g. starches, gums, alcohol sugar, polysaccharides, dextrin or containing high or low amount of carbohydrate
• CPC Class Codes: A23G 3/346 Finished or semi-finished products in the form of powders, paste or liquids A23G3/343 takes precedence
• CPC Class Codes: A23L 2/52 Adding ingredients adding preservatives A23L2/44
• CPC Class Codes: A23L 29/244 from corms, tubers or roots, e.g. glucomannan starch A23L29/212
• CPC Class Codes: A61K 31/702 Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• CPC Class Codes: A61K 31/715 Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
• CPC Class Codes: A61K 31/733 Fructosans, e.g. inulin
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/12 Antidiarrhoeals

Abstract

A method is provided for reducing the duration of diarrhea and recurrent episodes of diarrhea in humans by enterally administering indigestible oligosaccharides prophylactically. More specifically, the present invention relates to a method using indigestible oligosaccharides or fructooligosaccharides (FOS) to reduce the duration and recurrence of diarrhea in a human wherein between 0.5 grams and 5 grams of at least one FOS selected from the group consisting of 1-kestose, nystose, and 1^F -β-fructofuranosyl nystose is administered to said human per day. The indigestible oligosaccharides can be produced through enzymatic synthesis, chemical techniques or isolated from plant materials and are administered in the form of a nutritional product, candy, tablets, chewing gum, lozenges, milk, yogurts, fermented products and the like.

Claims

1. A method of reducing the duration of diarrhea in a human, said method comprises enterally administering nystose and 1^F -β

-fructofuranosyl nystose and mixtures thereof, on a prophylactic basis to said human in an amount effective to reduce the duration of diarrhea.

2. The method of claim 1 where said mixture of fructooligosaccharides is administered in a nutritional product.

3. The method of claim 2 wherein the nutritional product is an infant formula, follow-on formula, toddler'"'"'s beverage, milk, yogurt, or fermented product.

4. The method of claim 2 wherein the nutritional product is an infant formula, follow-on formula, toddler'"'"'s beverage, milk, yogurt, or fermented product.

5. The method of claim 1 wherein said mixture of fructooligosaccharides is administered in a candy a chewing gum, a tablet, a lozenge or a liquid.

6. The method of claim 1 wherein the mixture of fructooligosaccharides is administered at a rate of at least 0.5 grams per day to 5 grams per day.

7. A composition useful for reducing the duration of diarrhea, said composition comprising a mixture of nystose and 1^F -β

-fructofuranosyl nystose.

8. A method for reducing the duration of diarrhea in a human, said method comprises enterally administering to said human at least 0.5 grams per day of a mixture of fructooligosaccharides in which the fructooligosaccharide is selected from nystose and 1^F -β

-fructofuranosyl nystose and mixtures thereof.